NCT03889275 2023-02-21
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
Clinical Trials
6 trialsNCT04261075 2022-08-15
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
MedImmune LLC
Phase 1 Completed
NCT03665129 2022-01-27
STELLAR-001
Innate Pharma
Phase 1 Terminated
NCT02900157 2021-01-14
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT03089645 2020-07-27
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
Phase 1 Completed
NCT02261220 2020-03-06
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed